Exploiting the promiscuity of imatinib

Abstract

The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 Å crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor. © 2009 BioMed Central Ltd.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 93,642

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

  • Only published works are available at libraries.

Similar books and articles

Analytics

Added to PP
2017-05-27

Downloads
2 (#1,819,493)

6 months
6 (#587,658)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Su Lee
University of Toronto

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references